Clinical trial
Capecitabine and 131I-huA33 in Patients With Metastatic Colorectal Cancer
NCT00291486 · Ludwig Institute for Cancer Research, Other · Completed
Key facts
| NCT number | NCT00291486 |
|---|---|
| Title | Capecitabine and 131I-huA33 in Patients With Metastatic Colorectal Cancer |
| Official title | Phase I Trial of Oral Capecitabine Combined With 131I-huA33 in Patients With Metastatic Colorectal Cancer |
| Lead sponsor | Ludwig Institute for Cancer Research, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Colorectal Neoplasms |
| Intervention type | Drug |
| Interventions | Capecitabine, 131I-huA33 (131-Iodine on humanised monoclonal antibody A33) |
| Enrollment | 19 |
| Start date | Oct 1, 2003 |
| Primary completion | Jan 3, 2008 |
| Completion | Aug 29, 2012 |
| First posted | Feb 14, 2006 |
| Last update posted | Oct 10, 2022 |
| Countries | Australia |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: